Search Results

Fractyl Health, Inc. announced that Dr. Harith Rajagopalan, CEO of Fractyl Health, and Dr. Timothy Kieffer, CSO of Fractyl Health, will participate in a virtual fireside chat at the upcoming Piper Sandler 2nd Annual Virtual Obesity Day on Wednesday, June 26, 2024 at 9:30 a.m. EDT.

Fractyl Health, Inc. announced that it will accelerate its REMAIN-1 clinical study, which is evaluating Revita’s efficacy in maintaining weight loss following the discontinuation of GLP-1 therapy.

Fractyl Health, Inc., a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes, announced that Dr. Harith Rajagopalan, CEO of Fractyl Health, will participate in a fireside chat at the upcoming BofA Securities 2024 Health Care Conference on Wednesday, May 15, 2024, at 4:20 p.m. PDT.

Fractyl Health, Inc. announced it will report financial results for the first quarter 2024 and provide business updates after market close on Monday, May 13, 2024.

Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today reported its first quarter 2024 financial results and provided business updates.

Fractyl Health announced the pricing of its initial public offering of 7,333,333 shares of common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $110.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Fractyl Health.